Prognostic values of the presence of disseminated tumor cells in the bone marrow in patients with disseminated stomach cancer before start of treatment with antitumor drugs


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The purpose of our study was to evaluate the frequency and prognostic value of the presence of disseminated tumor cells (DTCs) in the bone marrow (BM) in patients with disseminated gastric cancer (GC). DTCs in BM of 43 patients with disseminated GC were determined by the flow cytometry (DTC-positive cases included those with the presence of at least 1 tumor cell per 10 million myelokaryocytes). The presence of DTCs in BM was detected in 28 of 43 patients (65.1%). In the absence of DTCs in the BM, the progression-free survival and overall survival of patients were significantly higher: 6.07 and 9.5 (log rank p=0.037) versus 11.67 and 22.5 (log rank p=0.029) months, respectively. DTCs in the BM was significantly more often detected in case of localization of primary tumor in the cardioesophageal junction (p=0.05) and in the low-grade and ring-shaped forms of adenocarcinoma (p=0.01 and p=0.024). There were no correlations of DTCs with the sex of patients, localization of distant metastases, the number of metastastatic sites. All patients underwent combined chemotherapy with mFOLFIRINOX. The presence of DTCs in BM is a negative prognostic factor for the progression-free survival and the overall survival of patients with disseminated GC.

Толық мәтін

Рұқсат жабық

Авторлар туралы

N. Besova

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

Email: besovans@mail.iu
PhD, Senior Reseaichei at the Department of Chemotherapy

E. Obarevich

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

M. Davydov

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

O. Beznos

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

N. Tupitsyn

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

Әдебиет тізімі

  1. Sieqel R., Naishadham D., Jemal A. Cancer statistics. 2012. CA Cancer J. Clin. 2012;62(1):10-29.
  2. Maehara Y., Hasuda S., Abe T., Oki E., Kakeji Y., Ohno S., Sugimachi K. Tumor Angiogenesis and Micrometastasis in Bone Marrow of Patients with Early Gastric Cancer. Clin. Cancer Res. 1998;4:2129-34.
  3. Maehara Y., Yamarnoto M., Oda S., Baba H., Kusumot T., Ohno S., Ichiyoshi Y., Sugimachi K. Cytokeratin-positive cells in bone marrow for identifying distant micrometastasis of gastric cancer. Br. J. Cancer. 1996;73:83-7.
  4. Jauch K.W., Heiss M.M., Gruetzner U., Funke I., Pantel K., Babic R., Eissner H.J., Riethmueller G., Schildberg F.W. Prognostic Significance of Bone Marrow Micrometastases in Patients With Gastric Cancer. J. Clin. Oncol. 1996;14(6):1810-17.
  5. Davydov M.I., Tupitsin N.N., Grigorieva T.A., et al. Assessment of minimal bone marrow involvement by flow cytometry in cancer patients. Haematopoiesis Immunol. 2014;12:8-17.
  6. Dasgupta A., Lim A.R., Ghajar C.M. Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol. Oncol. 2017;11:40-61.
  7. Joosse S.A., Gorges T.M., Pantel K. Biology, detection, and clinical implications of circulating tumor cells EMBO. Mol. Med. 2015;7(1):1-11.
  8. Kusumbe A.P. Vascular niches for disseminated tumour cells in bone. J. Bone Oncol. 2016;5:112-16.
  9. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., Schlimok G., Diel I.J., Gerber B., Gebauer G., Pierga J.Y., Marth C., Oruzio D., Wiedswang G., Solomayer E.F., Kundt G., Strobl B., Fehm T., Wong G.Y., Bliss J., Vincent-Salomon A., Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 2005;353:793-802.
  10. Kollermann J., Heseding B., Helpap B., Kollermann M.W., Pantel K. Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer. Int. J. Cancer. 1999;84: 145-49.
  11. Pantel K., Izbicki J., Passlick B., Angstwurm M., Haussinger K., Thetter O., Riethmüller G. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 1996;347:649-53.
  12. Lindemann F., Schlimok G., Dirschedl P., Witte J., Riethmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet. 1992;340:685-89.
  13. Effenberger K.E., Schroeder C., Eulenburg C., Reeh M., Tachezy M., Riethdorf S., Vashist Y.K., Izbicki J.R., Pantel K., Bockhorn M. Disseminated tumor cells in pancreatic cancer-an independent prognosticator of disease progression and survival. Int. J. Cancer. 2012;131:E475-83.
  14. Vashist Y.K., Effenberger K.E., Vettorazzi E., Riethdorf S., Yekebas E.F., Izbicki J.R., Pantel K. Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer. Ann. Surg. 2012;255:1105-12.
  15. Broll R., Lembcke K., Stock C., Zingler M., Duchrow M., Schimmelpenning H., Strik M., Muller G., Kujath P, Bruch H.P Tumor cell dissemination in bone marrow and peritoneal cavity. An immunocytochemical study of patients with stomach or colorectal carcinoma. Langenbecks Arch. Chir. 1996; 381(1):51-8.
  16. Kim H.S., Yi S.Y., Jun H.J., Lee J., Park J.O., Park Y.S., Jang J., Kim H.J., Ko Y., Lim H.Y., Kang W.K. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology. 2007;73:192-97.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2017

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>